Free Trial

Carmell (NASDAQ:CTCX) Shares Down 2.8% - Here's What Happened

Carmell logo with Medical background

Shares of Carmell Co. (NASDAQ:CTCX - Get Free Report) dropped 2.8% during trading on Thursday . The company traded as low as $2.38 and last traded at $2.45. Approximately 18,767 shares were traded during trading, a decline of 100% from the average daily volume of 4,290,529 shares. The stock had previously closed at $2.52.

Carmell Stock Performance

The stock has a 50 day moving average price of $2.09 and a 200 day moving average price of $0.91.

Institutional Trading of Carmell

A hedge fund recently bought a new stake in Carmell stock. Citadel Advisors LLC acquired a new position in Carmell Co. (NASDAQ:CTCX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 187,565 shares of the company's stock, valued at approximately $54,000. Citadel Advisors LLC owned 0.90% of Carmell at the end of the most recent reporting period. 24.22% of the stock is currently owned by institutional investors.

About Carmell

(Get Free Report)

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.

Further Reading

Should You Invest $1,000 in Carmell Right Now?

Before you consider Carmell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Carmell wasn't on the list.

While Carmell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines